Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

NCT02125344 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT02125344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02125344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
January 30, 2017
Enrollment
961 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female nos, her2 positive breast cancer, inflammatory breast cancer, invasive ductal breast cancer, mucinous breast cancer stage ii, tubular breast cancer stage ii, tubular breast cancer stage iii